Pediatr. praxi. 2008;9(1):12-14

Kawasaki syndrome

MUDr. Petr Jehlička1, MUDr. Václav Lád1, doc. MUDr. Dalibor Sedláček CSc2
1 Dětská klinika FN a LF UK v Plzni
2 Infekční klinika FN a LF UK, Plzeň

The authors present a review-article on current views at mucocutaneous – lymphonodal (Kawasaki) syndrome, usually accompanied with accute vasculitis, first of all affecting coronary arteries. The etiology of this disease is not sufficiently explained till this time, infectious or immune-mediated contribution is discussed. The pediatrician can be confronted with Kawasaki syndrome and its differential diagnostics and therapeutic approach in the routine practice.

Keywords: Kawasaki syndrome, vasculitis, children

Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jehlička P, Lád V, Sedláček D. Kawasaki syndrome. Pediatr. praxi. 2008;9(1):12-14.
Download citation

References

  1. Anderson MS, Todd JK, Glode MP. Delayed diagnosis of Kawasaki syndrome: an analysis of the problem. Pediatrics. 2005; 115(4): 428-433. Go to original source... Go to PubMed...
  2. Boven K et al. Atypical Kawasaki disease: an often missed diagnosis. Eur J Pediatr 1992; 151: 577-580. Go to original source... Go to PubMed...
  3. Brogan PA. What's new in the aetiopathogenesis of vasculitis? Pediatr Nephrol. 2007; 22: 1083-1094. Go to original source... Go to PubMed...
  4. Burns JC, Shimizu C, Gonzalez E et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J Infect Dis 2005; 192: 344. Go to original source... Go to PubMed...
  5. Cremer HJ. Kawasaki-Syndrom Frühe Diagnose und Therapiebeginn wichtig. Pädiatrie Hautnah 2004; (8): 442-446.
  6. Doležalová P, Telekešová P, Němcová D, Hoza J. Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey. J Rheumatol. 2004; 31(11): 2295-2299. Go to PubMed...
  7. Doležel Z, Knetigová M, Dostálová D, Petrželka J, Štarha J. Jaká je Vaše diagnóza? Pediatr. pro Praxi 2005; 6(5): 258-262.
  8. Esper F, Shapiro ED, Weibel C et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005; 191: 499. Go to original source... Go to PubMed...
  9. Freeman AF, Hulman ST. Kawasaki disease: Summary of the American Heart Association Guidelines Am Fam Physician 2006; 74: 1141-1148. Go to PubMed...
  10. Chang, LY, Chiang, BL, Kao, CL, et al. Lack of association between infection with a novel human coronavirus (HCoV), HCoV-NH, and Kawasaki disease in Taiwan. J Infect Dis 2006; 193: 283. Go to original source... Go to PubMed...
  11. Chen HH, Liu PM, Bong CN, Wu YT, Yang KD, Wang CL. Methylprednisolone pulse therapy for massive lymphadenopathy in a child with intravenous immunoglobulin-resistant Kawasaki disease. J Microbiol Immunol Infect. 2005; 38(2): 149-152.
  12. Kawasaki, T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967; 16: 178.
  13. Newburger JW, Takahashi M, Gerber MA et al. Diagnosis, treatment, and long-term management of Kawasaki disease a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, Council on cardiovascular disease in the young, American Heart Association. Circulation 2004; 110: 2747-2771. Go to original source... Go to PubMed...
  14. Newburger JW, Takahashi M, Gerber MA et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Pediatrics 2004; 114: 1708-1733. Go to original source... Go to PubMed...
  15. Raman V, Kim J, Sharkey A, Chatila T. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J. 2001; 20(6): 635-637. Go to original source... Go to PubMed...
  16. Stenbog EV, Windelborg B, Horlyck A, Herlin T. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease. Scand J Rheumatol. 2006; 35(4): 318-321. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.